Nutromics, a Brunswick, Australia-based MedTech startup, raised US$14M in funding.
The round was led by Dexcom Ventures, VU Venture Partners, and Artesian Investments.
This latest round of funding will support an expansion of clinical studies, expansion of R&D team and investment across both Australian and United States hubs.
Founded in 2017 by Peter Vranes (CEO) and Hitesh Mehta (COO), Nutromics is a developing a wearable diagnostic platform that uses DNA technology to enable tracking for multiple targets in the human body using a single patch. The DNA sensor technology will provide clinicians and patients with continuous and real-time diagnostic information ranging from hard-to-dose drugs, like vancomycin, to biological markers for conditions such as kidney disease.
The company will complete world-first in-human clinical studies of its first DNA sensors in 2022, as well as its integrated alpha prototype device.
FinSMEs
08/09/2022